HLA-A2.1 and human ECM1 double-knock-in mouse mammary cancer cell line (E0771) was subcutaneously injected in HLA-A2.1 transgenic mice to construct an allograft tumour model for investigating the immune activation and the antitumour effects induced by LA under the same condition (Fig. 7a). Here, ECM1 is linked to breast cancer.